Lilly's Oral Weight Loss Pill: A Game Changer?

0:00In Durham, it's March 18th, and here's what is going on. Eli Lilly Stock has soared with a market cap of $883 billion, and returns topping 1,500% over. The past decade, even with dividends reinvested, still is down 13% from recent peaks after posting $65.2 billion in revenue last year, up a huge 45%. Now HSBC has turned bearish, downgrading the shares to reduce from hold and slashing its price target to $850 from $1,070, while the stock trades around $989. Analysts expect the obesity drug market to hit over $150 billion someday, but HSBC sees a more modest 80-100, $20 billion by 2032. They worry sales growth comes more from pricing than standout products, with cuts looming in 2026 that could squeeze profits. Income investors might pause because Lilly's dividend yield stays low, despite nearly 30 years of payouts, and 12 straight years of raises at.

1:0611% annually, the company dishes out about $6.92 per share each year, with plenty of cash flow rooms to keep boosting it, even as free cash. Flow could jump from $9 billion in 2025 to $47 billion by 2030. A big test comes with Orphoric Lippron, Lilly's oral weight loss pill up for approval, possibly by April 2026. HSBC flags risks like lower patient stickiness compared to injections, though it's easier to take daily with no food or water rules facing stiff. Competition from Novo Nordisk's options already gaining traction. Wall Street targets for Lilly range wildly from $850 to $2,000, so opinions split sharply. Keep an eye on the pill's lost success and Medicare coverage starting no later than July 1st, which could boost volumes and counter pricing lows, across obesity, oncology, and more. The Daily News Now is powered by our sponsor, Link in the Description.

2:07Do not just fall asleep, drift into what you are listening to, S-O-L-I-SoliPillow.com. Made in AI.